Scientists believe ibogaine can help veterans overcome PTSD
Scientists are investigating ibogaine, a banned hallucinogenic compound derived from an African shrub, as a potential treatment for PTSD in military veterans. Early trials with US special forces veterans in Mexico showed significant reductions in PTSD, depression, and anxiety symptoms after a single ibogaine session. Researchers are still uncertain whether the drug's therapeutic effects stem from its chemical properties or the intense psychedelic experiences it induces.
- ▪Ibogaine is a controlled substance in the US but is unregulated in Mexico, where clinical trials with veterans have taken place.
- ▪A study involving 30 US special forces veterans found improved PTSD, depression, and anxiety symptoms after ibogaine treatment.
- ▪Participants who had more intense psychedelic experiences during treatment showed greater symptom improvement, according to follow-up research.
- ▪Ibogaine has also been studied for its potential to treat drug addiction, with interest dating back to the 1960s.
- ▪The drug is traditionally used in spiritual and healing ceremonies in central western Africa.
- ▪Stanford University researchers monitored the treatment progress of veterans receiving ibogaine in Mexico.
Opening excerpt (first ~120 words) tap to expand
Ibogaine is a banned hallucinogenic drug. Scientists believe it can help veterans overcome PTSD2 days agoShareSaveAdd as preferred on GoogleChris MarshallGetty Images(Credit: Getty Images)Trials on veterans suggest the potent hallucinogen could provide a new treatment for PTSD, but scientists still don't know how it works.Elias Kfoury was making what he considered to be a last-ditch attempt to remedy years of deep psychological pain. Lying on his back in a clinic in Tijuana, Mexico, the former US Navy special operations medic was deep under the influence of ibogaine, a potent psychedelic taking him on an immersive journey through old memories.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Bbc.
Discussion
0 commentsMore from Bbc
